Market Overview

Dr. Reddy's Q2 & H1 FY20 Financial Results

Share:

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY) today announced its consolidated financial results for the quarter and the half year ended September 30, 2019 under International Financial Reporting Standards (IFRS).

Q2 Performance Summary

H1 Performance Summary

 

Rs. 4,801 Cr

Revenue

[Up: 25% QoQ; 26% YoY]

Rs. 8,644 Cr

Revenue

[Up: 15% YoY]

 

57.5%

Gross Margin

[Q1 FY20: 51.7%; Q2 FY19: 55.0%]

54.9%

Gross Margin

[H1 FY19: 55.4%]

 

Rs.1,678 Cr

SGNA expenses

[Up: 39% QoQ, 36% YoY]

Rs. 2,884 Cr

SGNA expenses

[Up: 18% YoY]

 

Rs. 366 Cr

R&D expenses

[7.6% of Revenues]

Rs. 727 Cr

R&D expenses

[8.4% of Revenues]

 

Rs. 766 Cr

Profit before Tax

[Down: 10% QoQ; Up: 33% YoY]

Rs. 1,616 Cr

Profit before Tax

[Up: 50% YoY]

Commenting on the results, Co-Chairman and MD, GV Prasad said, "I am pleased with our performance across the businesses and strong cash generation during the quarter. We are progressing well in execution of our strategy and in our transformation journey on quality and efficiency."

All amounts in millions, except EPS All US dollar amounts based on convenience translation rate of I USD = Rs. 70.64

Dr. Reddy's Laboratories Limited and Subsidiaries

Consolidated Income Statement

 

Particulars

Q2 FY20

Q2 FY19

YoY

Gr %

Q1 FY20

QoQ

Gr%

($)

(Rs.)

($)

(Rs.)

($)

(Rs.)

Revenues

680

48,009

538

37,978

26

544

38,435

25

Cost of Revenues

289

20,389

242

17,081

19

263

18,576

10

Gross Profit

391

27,620

296

20,897

32

281

19,859

39

Operating Expenses

 

 

 

 

 

 

 

 

Selling, General & Administrative expenses

238

16,777

175

12,372

36

171

12,065

39

Research and Development expenses

52

3,662

58

4,120

(11)

51

3,609

1

Other operating (income)

-2

-135

-9

-641

(79)

-53

-3,759

(96)

Results from operating activities

104

7,316

71

5,046

45

112

7,944

(8)

Net finance (income)

-3

-231

-9

-625

(63)

-6

-393

(41)

Share of (profit) / loss of equity accounted investees

-2

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com